LATAM’s healthcare systems could benefit hugely from what pharma has to offer – but only with value-based collaborations. This is what brings 200+ executives from the world’s leading pharma companies together in Miami. Well-known names in life sciences like Novartis, Teva, Roche, GSK – but also Microsoft and AWS – will discuss the fine details of aligning healthcare transformations in LATAM with doctor-patient-pharma interactions.Find out more
When a large event is organized by eyeforpharma, it immediately attains the scale where no heavy promotion is needed. This time, over 700 pharma leaders are expected to participate actively, including Astellas, Novartis, Bayer, Ferring, Teva, and GSK, to name just a few. All of these will share their experience and success cases around the single but broad topic: how to increase the impact pharma is making on patients?Find out more
Digital communications are here and there, and pharma companies just can’t ignore the latest trends. That’s why, from time to time industry movers gather to discuss what’s new in medical marketing and share successful cases on addressing the existing HCPs engagement challenges.
The event in Vilnius is right one of a kind – an ideal platform for pharma key opinion leaders to share practical insights and find brand new ways of interaction with the target audience. This year’s speakers feature Vivanti, Berlin Chemie, BrandPharma and other companies, as well as some of the industry-specific agencies’ representatives.
ProcureCon has already proven for a couple of years in a row to be one of the best networking platforms for C-level procurement professionals. This year, the 3-days event will gather Senior Procurement Executives from the healthcare sector to discuss hot industry topics and share best practices.Find out more
If there’s one day when all pharma’s most significant stakeholder’s are not to be found in their offices – it’s the day of eyeforpharma conference in Barcelona. This year’s attendance amounts to 1200+ people, a whole 1200+ of networking opportunities and engaging debates on most acute challenges of the industry.Find out more